Welcome to our dedicated page for Absci news (Ticker: ABSI), a resource for investors and traders seeking the latest updates and insights on Absci stock.
Absci Corporation (Nasdaq: ABSI) is a clinical-stage biopharmaceutical and biotechnology company that frequently issues news related to its generative AI-driven drug discovery platform and internal pipeline of biologic therapeutics. News coverage for Absci often centers on developments in its lead AI-designed antibody programs, platform collaborations, and corporate updates that are relevant to investors and the broader life sciences community.
A major focus of recent Absci news is ABS-201™, an anti-prolactin receptor (PRLR) antibody being developed for androgenetic alopecia and investigated for endometriosis. Press releases have described preclinical human ex vivo data on hair growth, the design and initiation of the Phase 1/2a HEADLINE trial in androgenetic alopecia, and plans for Phase 2 development in endometriosis. Updates also highlight scientific advisory board appointments, key opinion leader seminars, and partnerships aimed at elevating patient perspectives in hair loss research.
Investors following ABSI news can also expect announcements on pipeline progress for programs such as ABS-101, ABS-301, and ABS-501, as well as drug creation partnerships with pharmaceutical, biotech, technology, and academic organizations. Absci has reported collaborations with cloud and hardware providers to support its AI Drug Creation platform, along with participation in healthcare and biotech investor conferences and major industry events.
This news feed aggregates Absci’s press releases and third-party coverage, including items on clinical trial milestones, scientific data presentations, financing and capital markets activity, and corporate governance changes. Readers interested in ABSI can use this page to monitor how Absci’s AI-enabled platform, internal therapeutic programs, and partnerships evolve over time and to track key events that may shape the company’s scientific and business trajectory.
Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has scheduled its first quarter 2025 earnings release and business updates for May 13, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss developments, financial results, and future outlook. Investors can access the live audio webcast through the company's investor relations website at investors.absci.com, where a replay will also be available after the event.
Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has announced its participation in two upcoming investor conferences in April 2025:
- H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference - Fireside chat scheduled for Wednesday, April 2 at 10:30 a.m. ET / 7:30 a.m. PT
- 24th Annual Needham Virtual Healthcare Conference - Fireside chat scheduled for Tuesday, April 8 at 3:45 p.m. ET / 12:45 p.m. PT
Investors and interested parties can access both live and archived webcasts of these fireside chat sessions through Absci's investor relations website at investors.absci.com.
Absci (NASDAQ: ABSI) reported its Q4 and full year 2024 financial results, highlighting significant progress in its AI Integrated Drug Creation platform. The company secured a $20 million strategic investment from AMD and established new partnerships with Owkin, Twist Bioscience, Invetx, and Memorial Sloan Kettering Cancer Center.
Key pipeline updates include ABS-101's advancement toward Phase 1 clinical studies in H1 2025, and ABS-201's development for androgenic alopecia targeting a potential U.S. market of 80 million individuals. The company's financial position shows Q4 2024 revenue of $0.7 million and a net loss of $29.0 million. Full-year 2024 results include revenue of $4.5 million and a net loss of $103.1 million.
With $112.4 million in cash and investments as of December 31, 2024, Absci expects to fund operations into the first half of 2027.
Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has scheduled the release of its fourth quarter and full year 2024 financial and operating results. The announcement will be made after market close on March 18, 2025.
The company will host a conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss business developments, financial results, and future outlook. Investors can access the live audio webcast through the company's investor relations website at investors.absci.com. A replay of the webcast will be available after the event.
Absci (Nasdaq: ABSI) has announced an inducement grant of stock options to a newly-hired non-executive employee. The grant, approved by the Compensation Committee under the 2023 Inducement Plan, includes options to purchase 162,800 shares of common stock at $3.42 per share, matching the closing price on March 3, 2025.
The stock option features a 10-year term with a four-year vesting schedule: 25% vests on the first anniversary, followed by the remaining 75% vesting in 36 approximately equal monthly installments. Full vesting will occur on the fourth anniversary, contingent on continued employment.
Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has announced its participation in the upcoming virtual KeyBanc Capital Markets Healthcare Forum. The company's management will engage in a fireside chat scheduled for Wednesday, March 19th, 2025 at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time). Investors and interested parties can access both live and archived webcasts of the presentation through Absci's investor relations website at investors.absci.com.
Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has announced its participation in the TD Cowen 45th Annual Health Care Conference in Boston, MA. The company's management will engage in a fireside chat on Monday, March 3rd at 3:10 p.m. Eastern Time (12:10 p.m. Pacific Time).
Interested parties can access both live and archived webcasts of the presentation through Absci's investor relations website at investors.absci.com.
Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has announced its participation in the upcoming Guggenheim Securities SMID Cap Biotech Conference in New York. The company's management will engage in a fireside chat on Wednesday, February 5th at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). Interested investors and stakeholders can access both live and archived webcasts of the presentation through Absci's investor relations website at investors.absci.com.
Absci (NASDAQ: ABSI) and Owkin have announced a strategic partnership to combine their AI platforms for drug discovery and development. The collaboration will focus on discovering and designing novel therapeutics in immuno-oncology, immunology, and inflammation.
Owkin will contribute its predictive AI models for target selection and therapeutic hypothesis validation using biomedical datasets and patient-derived organoids. Absci will utilize its generative AI Drug Creation platform and de novo antibody design models to develop therapeutic candidates against these novel targets.
This partnership marks Absci's fourth drug creation partnership in 2024, meeting the company's yearly outlook. Both companies bring significant industry partnerships to the table, with Absci's existing collaborations with AstraZeneca and Merck, and Owkin's work with Sanofi and BMS.
Absci (NASDAQ: ABSI) has announced a strategic collaboration with AMD focused on AI drug discovery advancement. The partnership includes a $20 million strategic investment from AMD through a private investment in public equity (PIPE) and will involve deploying AMD Instinct™ accelerators and ROCm™ software to power Absci's AI drug discovery workloads, including de novo antibody design models.
The collaboration aims to enhance Absci's biological modeling capabilities by providing optimized AI solutions that offer improved performance, reduced infrastructure costs, and faster innovation cycles. The partnership will showcase the performance of AMD's Instinct accelerators in complex biological applications, including Absci's IgDesign1 model, which is the first in vitro validated inverse folding model for antibody design.
FAQ
What is the current stock price of Absci (ABSI)?
What is the market cap of Absci (ABSI)?
